Cannabis and Federal Employment: Security Clearance Implications in the Rescheduling Era

When cannabis was reclassified from Schedule I to Schedule III in October 2025, it was the most significant federal cannabis policy shift since the Controlled Substances Act was enacted in 1970. For millions of Americans, it signaled a dramatic change in how the federal government views cannabis. But for the approximately 4.2 million people who hold federal security clearances — and the 2.1 million federal civilian employees who are subject to drug-free workplace policies — the picture is considerably more complicated.

The core tension is this: rescheduling changed the legal classification of cannabis, but it did not legalize recreational use at the federal level. Cannabis remains a controlled substance. And for federal employees and clearance holders, that distinction is everything.

What Rescheduling Actually Changed

Schedule III classification places cannabis in the same regulatory category as drugs like ketamine, anabolic steroids, and certain codeine formulations. This has real consequences:

For research: Schedule III substances are dramatically easier to study. The DEA licensing requirements that made cannabis research nearly impossible under Schedule I have been substantially reduced, opening the door for clinical trials and academic studies that were previously blocked.

For taxation: Cannabis businesses are no longer subject to Section 280E of the Internal Revenue Code, which prevented them from deducting standard business expenses. This has been a financial game-changer for the industry — as detailed in our Q1 2026 industry review.

For medical legitimacy: Schedule III classification explicitly acknowledges that cannabis has accepted medical use, resolving a long-standing contradiction between federal scheduling and the reality of 40+ state medical programs.

For prescriptions: In theory, Schedule III substances can be prescribed by physicians (not just “recommended,” as was the case under state medical programs). However, the practical implementation of this change has been slow, with the FDA still working on specific regulatory frameworks for cannabis prescribing.

What Rescheduling Did Not Change

Here is where federal employees and clearance holders need to pay close attention.

Cannabis is still a controlled substance. Schedule III is not Schedule V, and it is certainly not descheduled. Federal law still prohibits the use of cannabis without a valid prescription, and the recreational use that is legal in 24 states remains federally illegal.

Federal drug-free workplace policies remain in effect. Executive Order 12564, signed in 1986, requires federal agencies to maintain drug-free workplaces. The Drug-Free Workplace Act of 1988 reinforces this. Neither has been amended to accommodate cannabis rescheduling. Federal employees are still subject to random drug testing, and a positive test for THC metabolites can still result in disciplinary action up to and including termination.

Security clearance adjudication guidelines have not been formally updated. The Adjudicative Guidelines used by the Defense Counterintelligence and Security Agency (DCSA) — which govern all federal security clearances — list illegal drug use as a disqualifying factor under Guideline H (Drug Involvement and Substance Misuse). While the guidelines allow for mitigation, current cannabis use remains a presumptive disqualifier.

The Gray Zone: How Agencies Are Actually Handling It

Despite the formal policy framework remaining largely unchanged, there has been a measurable shift in how federal agencies and adjudicators approach cannabis in practice since rescheduling.

Prior Use Disclosure

In 2023, the Biden administration issued updated guidance indicating that prior cannabis use should not automatically disqualify an applicant from federal employment or security clearance eligibility. This guidance, which was issued before rescheduling, reflected a pragmatic recognition that strict enforcement was eliminating a huge portion of the qualified applicant pool — particularly younger candidates.

Post-rescheduling, this trend has accelerated. Adjudicators are increasingly treating prior cannabis use — especially use that occurred in a state where it was legal at the time — as a mitigable factor rather than a disqualifier. The key factors that adjudicators weigh include:

• Recency: How long ago did the use occur? The informal “one year” rule (demonstrating at least 12 months of abstinence) remains widely applied, though some agencies accept shorter periods.
• Frequency: Occasional experimental use is treated far more leniently than habitual daily use.
• Context: Use in a state with legal adult-use cannabis is viewed more favorably than use in a prohibition state.
• Honesty: Disclosure of prior use is viewed positively. Concealment of use that is later discovered is viewed as a serious integrity issue that can be more damaging to a clearance case than the use itself.

Current Use

This is where the situation remains unambiguous: current use of cannabis without a valid federal prescription remains disqualifying for security clearance holders and federal employees. No amount of state-level legality changes this calculation. The federal government has not issued any guidance suggesting otherwise.

The distinction between “prior use” (increasingly tolerated) and “current use” (still disqualifying) is the bright line that federal employees and clearance holders must understand.

Medical Use With a Prescription

The most novel and legally uncertain area involves employees who obtain a legitimate prescription for cannabis under the emerging Schedule III prescribing frameworks. In theory, using a Schedule III substance with a valid prescription should be treated the same as using any other prescribed controlled substance — no different from a clearance holder who takes prescribed Adderall or oxycodone.

In practice, agencies are still developing policy on this point. The Department of Defense issued interim guidance in January 2026 indicating that medical cannabis use with a valid prescription would be evaluated on a case-by-case basis, considering factors like the medical condition being treated, the prescribing physician’s credentials, and the impact on the employee’s ability to perform their duties. Other agencies have been slower to issue guidance.

The safest interpretation as of April 2026: medical cannabis with a federal prescription is likely to be accepted by most agencies for non-sensitive positions, but remains risky for positions requiring Top Secret or Sensitive Compartmented Information (TS/SCI) clearances, where the adjudicative bar is higher.

Practical Guidance for Federal Employees and Applicants

Based on the current policy landscape, here is straightforward guidance for different scenarios:

If You Are a Current Federal Employee or Clearance Holder

Do not use cannabis recreationally. Full stop. Regardless of your state’s laws, regardless of rescheduling, recreational cannabis use remains incompatible with federal employment and security clearance status. The risk of a positive drug test leading to clearance revocation and termination is real and has not diminished post-rescheduling.

If you believe medical cannabis would benefit your health, consult with your agency’s employee assistance program (EAP) and a physician familiar with the federal prescribing framework before taking any action. Do not self-medicate with state medical cannabis products and assume that rescheduling provides cover.

If You Are Applying for a Federal Position or Clearance

Disclose prior use honestly on your SF-86 or other application forms. The penalty for dishonesty far exceeds the penalty for prior cannabis use. Adjudicators are professionals who see thousands of applications with cannabis use disclosures — it is routine, not scandalous.

Demonstrate abstinence for a minimum of 12 months before applying. This is the most commonly cited mitigation benchmark across agencies. Longer periods of abstinence strengthen your case.

Do not use cannabis between submitting your application and receiving your clearance, even if you live in a legal state. This is one of the most common and avoidable mistakes applicants make.

If You Are a Contractor

Federal contractor drug testing policies vary by agency and contract. Some mirror the federal employee framework closely; others are more lenient. Review your specific contract requirements and employer policies rather than assuming a one-size-fits-all standard.

Legislative Outlook

Several pieces of pending legislation could significantly change this landscape:

The Cannabis Employment Protection Act, introduced in early 2026, would prohibit federal agencies from denying employment or clearances solely on the basis of prior cannabis use in legal states. It has bipartisan support but faces an uncertain timeline.

Amendments to Executive Order 12564 have been discussed within the administration but not formally proposed. Any amendment would need to navigate the political complexities of appearing “soft on drugs” while also modernizing a 40-year-old policy framework.

Agency-specific policy updates are likely to be the most impactful near-term changes. Individual agencies have significant discretion in how they implement drug-free workplace policies, and several — including NASA, DOE, and parts of DHS — are actively reviewing their cannabis-related policies.

The Compliance Technology Layer

For organizations navigating this complex landscape, the seed-to-sale tracking systems that underpin legal cannabis markets play an important role. These systems create verifiable records of legal purchases that can support employees who need to demonstrate that their prior use occurred within legal state frameworks — a factor that adjudicators increasingly consider relevant.

The Bottom Line

Rescheduling was a historic step, but it was a step on a longer road. For federal employees and clearance holders, the practical reality in 2026 is that cannabis policy exists in a transitional state — more lenient than five years ago, but still fundamentally restrictive for current use. The safe course is to understand exactly where the lines are, stay on the right side of them, and advocate for policy change through proper channels rather than assuming that the law has caught up to cultural attitudes.

The trend is unmistakably toward greater tolerance. But trends and policies operate on different timelines, and until formal policies change, the old rules still apply where it matters most.